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JOURNAL OF HEPATOLOGYTo the Editor:
We thank Dr. Ridruejo et al. for their stimulating comments on
our review [1]. Their interesting results on entecavir efﬁcacy
and safety in HBV-positive kidney transplanted or candidates
for kidney transplantation patients [2] are very convincing and
conﬁrm the recommendation of the published guidelines [3,4].
Eleven patients (3 kidney transplanted recipients, 8 hemodialy-
sed patients, and 1 end stage renal disease patient) were treated
with entecavir during a median of 2 ± 0.86 years.
First, entecavir therapy was efﬁcient on HBV DNA levels: 6
patients (54.5%) had HBV DNA undetectable and 5 patients had
a signiﬁcant decrease in serum HBV DNA levels from
6.84 ± 1.45 log10 IU/ml (range 5.21–9.04) to 1.73 ± 2.11 log10 IU/
ml (range 0.78–4.72) at the end of follow-up. The shorter dura-
tion of entecavir treatment in 5 patients who had detectable
HBV DNA at the end of follow-up (1.06 ± 1.03 years) probably
explains the lower antiviral efﬁcacy than in 6 patients who had
HBV DNA undetectable (2.33 ± 0.56 years). It would be interest-
ing to deﬁne if the 5 lamivudine-resistant patients before the
introduction of entecavir therapy were the 5 patients who had
experienced a lower antiviral efﬁcacy.
Second, 7 out of 9 HBeAg-positive patients (77.7%) had an
anti-HBe seroconversion during entecavir treatment and 1 of
them had an anti-HBs seroconversion.
Although the small cohort of patients, these ﬁndings are excit-
ing and encouraging, as far as the authors do not ﬁnd signiﬁcant
changes in renal function or haematological parameters.
These data are concordant with others recently published in
HBV lamivudine-resistant kidney transplanted patients who
respond to entecavir salvage treatment [5,6] or to our own expe-
rience: we have treated 45 kidney recipients, including 18 treated
by entecavir alone (n = 7) or in combination with adefovir (n = 4)
or tenofovir (n = 7). HBV DNA was undetectable in 93.4% of
patients and more importantly viral suppression was associated
with a signiﬁcant improvement in kidney and patient survival
as compared to our historical data (work in progress).Journal of Hepatology 2012 vol. 56 j 993–999 999
